μμλμ½λ¦°
μΌν μμλμ½λ¦°μ μ΄λ¨κΈ° μμ©ν νλΆκ·Ήμ± 골격근 μ΄μμ (λ§λΉμ )μ λλ€. **μ£Όμ μμ μμ :** * **μ§ν΅ λλ μ§μ ν¨κ³Ό μμ:** μμλμ½λ¦°μ ν΅μ¦ μνλ μμ μμ€μ μ ν μ 곡νμ§ μμ΅λλ€. νμλ μμ ν κΉ¨μ΄ μκ³ ν΅μ¦μ λλ μ μμ§λ§ μμ ν λ§λΉλ μνκ° λ©λλ€. λ°λμ μ μ ν μ§μ μ , λ§μ·¨μ λ° μ§ν΅μ μ ν¨κ» μ¬μ©ν΄μΌ ν©λλ€. * **νΈν‘ μ§μ νμ:** ν‘격λ§κ³Ό λκ°κ·Όμ λ§λΉμν€λ―λ‘ μ½ν¨κ° μ¬λΌμ§ λκΉμ§ κΈ°κ³μ νκΈ°κ° νμμ μ λλ€. * **μμμ μ©λ:** μ£Όλ‘ κΈ°κ΄λ΄ μ½κ΄(μ μ μ°μ μ½κ΄), μμ /μ§λ¨ μ μ°¨λ₯Ό μν λ¨κΈ° κ·Όμ‘ μ΄μ λλ κ²½λ ¨ μ€ κ·Όμ‘ μμΆ κ°μμ μ¬μ©λ©λλ€. * **μ’ κ° μ°¨μ΄:** μ¬λκ³Ό λλΆλΆμ λλ¬Όμμλ μμ© μκ°μ΄ λ§€μ° μ§§μ§λ§(2-3λΆ), κ°μμλ νΉμ΄νκ² μμ© μκ°μ΄ μ°μ₯(μ½ 20λΆ)λλ νΉμ§μ 보μ λλ€. * **νλμ μ¬μ©:** μμνμμμ μ¬μ©μ λΆμμ©μ΄ μ κ³ μμ μ΄ κ°λ₯ν λΉνλΆκ·Ήμ± μ½λ¬Ό(μ: μνΈλΌμΏ 리μ, λ‘μΏ λ‘λ)λ‘ λ체λλ μΆμΈμ λλ€.
μμ© κΈ°μ : Succinylcholine acts as a depolarizing neuromuscular blocker. * **Binding:** It acts as a structural analog of acetylcholine (ACh) and binds to **nicotinic acetylcholine receptors (nAChRs)** at the motor endplate of the neuromuscular junction. * **Depolarization:** Unlike ACh, which is instantly degraded by acetylcholinesterase, succinylcholine remains bound, causing prolonged depolarization of the muscle membrane. This initial depolarization manifests clinically as transient muscle twitches (**fasciculations**). * **Paralysis:** Because the membrane cannot repolarize, it becomes unresponsive to subsequent ACh release β **flaccid paralysis** (Phase I block). * **Metabolism:** The blockade persists until succinylcholine diffuses away from the receptor and is rapidly hydrolyzed by **plasma pseudocholinesterase** (butyrylcholinesterase) in the blood.
λλ¬Ό μ’ λ³ μ©λ
- Muscle relaxation Β· 0.06 mg/kg Β· IV Β· Single dose
- Muscle relaxation Β· 0.11 mg/kg Β· IV Β· Single dose
- Muscle relaxation Β· 0.088-0.11 mg/kg Β· IV, IM Β· Single dose Β· See Precautions. ARCI UCGFS Class 2 Drug. 0.088 mg/kg IV may paralyze skeletal muscles without causing respiratory depression, but higher doses cause apnea.
- Muscle relaxation Β· 0.07 mg/kg Β· IV Β· Single dose
- Muscle relaxation Β· 0.22 mg/kg Β· IV Β· Single dose
- To relax an animal to allow intubation Β· 0.5-1 mg/kg Β· IM Β· Single dose Β· Especially helpful with turtles and crocodilians.
μ©λμ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μ°Έκ³ μλ£μ λλ€. νμ μ΅μ λΌλ²¨κ³Ό κ°λ³ νμμ λν΄ νμΈνμμμ€.
ν¬μ¬ κ²½λ‘
κΈκΈ°
- Severe liver disease
- Chronic anemias
- Chronic malnourishment
- Glaucoma or penetrating eye injuries
- Predisposition to malignant hyperthermia
- Increased CPK values with resultant myopathies
- Recent use of organophosphate agents
μ΄μλ°μ
- Muscle soreness
- Histamine release
- Malignant hyperthermia
- Excessive salivation
- Hyperkalemia
- Rash
- Myoglobinemia
- Myoglobinuria
- Bradycardia
- Tachycardia
- Hypertension
- Hypotension
- Arrhythmias
μ½λ¬Ό μνΈμμ©
- Amphotericin B Β· May increase succinylcholine's effects by causing electrolyte imbalances
- Digoxin Β· Succinylcholine may cause a sudden outflux of potassium from muscle cells, causing arrhythmias in digitalized patients
- Opiates Β· Potential for increased incidences of bradycardia and sinus arrest
- Thiazide Diuretics Β· May increase succinylcholine's effects by causing electrolyte imbalances
- Aminoglycosides Β· May increase or prolong neuromuscular blockade
- Inhalant Anesthetics (Isoflurane, Desflurane) Β· May increase or prolong neuromuscular blockade
- Antiarrhythmics (Quinidine, Lidocaine, Procainamide) Β· May increase or prolong neuromuscular blockade
- Beta-Adrenergic Blockers Β· May increase or prolong neuromuscular blockade
- Corticosteroids Β· May increase or prolong neuromuscular blockade
- Magnesium Salts Β· May increase or prolong neuromuscular blockade
- Organophosphates Β· May increase or prolong neuromuscular blockade (Contraindicated)
λͺ¨λν°λ§
- Level of muscle relaxation
- Cardiac rate and rhythm (ECG)
- Respiratory depressant effect (Apnea)
- Oxygenation (Pulse oximetry) and Ventilation (Capnography)
- Body temperature (risk of malignant hyperthermia)
κ³Όμ©λ
Inadvertent overdoses, or standard doses in patients deficient in pseudocholinesterase, may result in **prolonged apnea**. * **Treatment:** Mechanical ventilation with 100% O2 must be maintained until full spontaneous recovery occurs. * **Phase II Block:** Repeated or prolonged high dosages may cause patients to convert from a depolarizing (Phase I) block to a non-depolarizing-like (Phase II) block.
VetSheet μ½λ¬Ό λ νΌλ°μ€λ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μμ¬κ²°μ 보쑰 λꡬμ΄λ©°, μ λ¬Έμ νλ¨μ΄λ μ μ‘°μ¬μ μ΅μ λΌλ²¨μ λμ νμ§ μμ΅λλ€.